Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 7, 2011, Pages 1991-1996

  Hoveyda, Hamid R ^a   Roy, Marie Odile ^a   Blanc, Sebastien ^a   Noël, Sophie ^a   Salvino, Joseph M ^b   Ator, Mark A ^b   Fraser, Graeme ^a  

^a Euroscreen SA   (Belgium)

^b CEPHALON INC   (United States)

Author keywords

Antipsychotic; NK3 antagonist; Pyrazole

Indexed keywords

3 ARYL 5 ACYLPIPERAZINYL PYRAZOLE DERIVATIVE; GSK 183390A; N (ALPHA ETHYLBENZYL) 3 METHYL 2 PHENYL 4 QUINOLINECARBOXAMIDE; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; OSANETANT; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; TALNETANT; UNCLASSIFIED DRUG;

AMINATION; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROLYSIS; ISOMERISM; LIPOPHILICITY; MEMBRANE PERMEABILITY; NONHUMAN; PROCESS OPTIMIZATION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL LINE, TUMOR; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; PYRAZOLES; RATS; RECEPTORS, NEUROKININ-3; STRUCTURE-ACTIVITY RELATIONSHIP;

RODENTIA;

EID: 79952488963     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.033     Document Type: Article

References (19)

1. Spooren, W.; Riemer, C.; Meltzer, H. Nat. Rev. Drug Disc. 2005, 4, 967.
2. Smith, P. W.; Dawson, L. A. Recent Patents CNS Drug Disc. 2008, 3, 1.
3. Giardina, G. A. M.; Raveglia, L. F. Expert Opin. Ther. Patents 1997, 7, 307.
4. See for example: (a) Smith, P. W.; Wyman, P. A.; Lovell, P.; Goodacre, C.; Serafinokwska, H. T.; Vong, A.; Harrington, F.; Flynn, S.; Bradley, D. M.; Porter, R.; Coggon, S.; Murkitt, G.; Searle, K.; Thomas, D. R.; Watson, J. M.; Martin, W.; Wu, Z.; Dawson, L. Bioorg. Med. Chem. Lett. 2009, 19, 837;
5. (b) Elliott, J. M.; Carling, R. W.; Chambers, M.; Chicchi, G. G.; Hutson, P. H.; Jones, A. B.; MacLeod, A.; Marwood, R.; Mensese-Lorente, G.; Mezzogori, E.; Murray, F.; Rigby, M.; Royo, I.; Russell, M. G. N.; Sohal, B.; Tsao, K. L.; Williams, B. Bioorg. Med. Chem. Lett. 2006, 16, 5748;
6. (c) Xiong, H.; Kang, J.; Woods, J. M.; McCauley, J. P., Jr.; Koether, G. M.; Albert, J. S.; Hinkley, L.; Gadient, R. A.; Simpson, T. R. Bioorg. Med. Chem. Lett. 2010. doi:10.1016/j.bmcl.2010.11.003.
7. 2+] causes a conformational change in the aequorin protein thereby eliciting a quantifiable luminescent signal. This method is adapted to detect agonist, antagonist or allosteric modulators of receptor activity.
8. Petruso, S.; Caronna, S.; Sferlazzo, M.; Sprio, V. J. Heterocycl. Chem. 1990, 27, 1277.
9. Bellemin, R.; Festal, D. J. Heterocycl. Chem. 1984, 21, 1017.
10. Given the good agreement between the radioligand binding and aequorin functional assays, the latter set of results will be principally used in foregoing SAR discussions.
11. Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. D. J. Med. Chem. 2002, 45, 2615.
12. No appreciable solubility difference between 4 and 5 was detectable at pH 7, although at pH 5 benzylpiperazine analog 5 was decidedly more soluble.
13. C log P values cited herein are calculated using ChemBioDraw (CambridgeSoft, v.12).
14. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization; Academic Press: Burlington, Massachusetts, 2008. Chapter 12.
15. Talnetant was made and characterized as per: (a) Giardina, G. A. M.; Sarau, H. M.; Farina, C.; Medhurst, A. D.; Grugni, M.; Foley, J. J.; Raveglia, L. F.; Schmidt, D. B.; Rigolio, R.; Vassallo, M.; Vecchietti, V.; Hay, D. W. P. J. Med. Chem. 1996, 39, 2281; Osanetant was purchased from Charnwood Molecular, UK. It was made and characterized as per:
16. (b) Giardina, G. A. M.; Grugni, M.; Rigolio, R.; Vassllo, M.; Erhard, K.; Farina, C. Bioorg. Med. Chem. Lett. 1996, 6, 2307;
17. (c) Chen, H. G.; Chung, F.-Z.; Goel, O. P.; Kesten, J. S.; Knobelsdorf, J.; Lee, H. T.; Rubin, J. R. Bioorg. Med. Chem. Lett. 1997, 7, 555.
18. For a report on the pharmacokinetic profile of talnetant, see Tables 2 and 3 in: Sarau, H. M.; Griswold, D. E.; Potts, W.; Foley, J. J.; Schmidt, D. B.; Webb, E. F.; Martin, L. D.; Brawner, M. E.; Elshourbagy, N. A.; Medhurst, A. M.; Giardina, G. A. M.; Hay, D. W. P. J. Pharmacol. Exp. Ther. 1997, 281, 1303. The reported values in Table 5 herein are in agreement with those in the cited reference.
19. For example: Martres, P.; Faucher, N.; Laroze, A.; Pineau, O.; Fouchet, M.-H.; Potvain, F.; Grillot, D.; Beneton, V. Bioorg. Med. Chem. Lett. 2008, 18, 6251. Compound 7 (GSK183390A) in the cited reference is depicted below and has been reported to have a clean 7-day toxicology profile in rats with no safety issues. (Chemical Equation Presented)